Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment in Patients With Pulmonary Arterial Hypertension

Next Previous
Trial Profile

PHIRST-1: Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment in Patients With Pulmonary Arterial Hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms PHIRST-1
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 11 Aug 2021 Results of pooled adult/pediatric population analysis assessing pharmacokinetics of tadalafil to explored in a pediatric phase Ib/II (NCT01484431; n=19) study and pooled with prior phase III (pulmonary arterial hypertension and response to tadalafil [PHIRST-1; NCT00125918; n=305]) adult data to develop the first population PK model for tadalafil in pediatric patients with pulmonary arterial hypertension, published in the Clinical Pharmacokinetics.
    • 14 Oct 2013 New trial record
    • 04 Sep 2013 Results for long-term safety and survival outcomes from open-label extension PHIRST2-Part 2 presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top